Sabine Bos
Analyst
- Name
- Ing. S. Bos
- Telephone
- 071 5274492
- s.bos@lacdr.leidenuniv.nl
- ORCID iD
- 0009-0007-1839-4481
Analyst
- LACDR
- Metabolomics and Analytics Centre
- Yin C., Nelen I., Harms A., Hartman R., Bos S., Nijgh-van Kooij C., Hankemeier T., Kindt A. & Lange E.C.M. de (2026), Longitudinal metabolomic profiling of biogenic amines in plasma and CSF, and their correlation, reveals sex-specific and age changes in TgF344 Alzheimer’s disease transgenic and wildtype rats, Fluids and Barriers of the CNS 23: 69.
- Goris M.M., Valdez M.E., Lamont L., Yang W., Harms A.C., Karu N., Bos S., Geerlings J.J.B., Ottenhoff T., Tsonaka R., Roukens A.H.E., Arbous M.S., Joosten S.A., Hankemeier T. & Kindt A. (2026), Tracking COVID-19 severity and progression through amines and lipid mediators, Journal of Medical Virology 98(7): e71030.
- Hosseinkhani F., Chevalier C., Marizzoni M., Park R., Bos S., Kindt Dunjko A.S.D., Duijn C.M. van, Harms A.C., Frisoni G.B. & Hankemeier T. (2025), Plasma and feces multiomics unveil cognition-associated perturbations of chronic inflammatory pathways of the gut-microbiota-brain axis, Alzheimer's & Dementia 21(10): 1-10 ( e70844).
- Noga M.J., Zielman R., Dongen R.M. van, Bos S., Harms A.C., Terwindt G.M., Maagdenberg A.M.J.M. van den, Hankemeier T. & Ferrari M.D. (2018), Strategies to assess and optimize stability of endogenous amines during cerebrospinal fluid sampling, Metabolomics 14: 44.
- Hankemeier T., Kaddurah-Daouk R., Koval V.V., Harms A.C., Moon I., Kuwahara H., Bos S., Marin S., Cascante M., Weinshilboum R. & Wang L. (2016), Studying individual differences in cancer drug efficacy using cell lines derived from patients, Clinical Pharmacology & Therapeutics 99: S103-S103.